Keybank National Association OH lessened its holdings in Pfizer Inc. (NYSE:PFE) by 1.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,166,070 shares of the biopharmaceutical company’s stock after selling 44,625 shares during the quarter. Pfizer accounts for approximately 0.9% of Keybank National Association OH’s investment portfolio, making the stock its 22nd biggest holding. Keybank National Association OH’s holdings in Pfizer were worth $148,729,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. First Command Bank raised its position in Pfizer by 131.5% during the second quarter. First Command Bank now owns 23,934 shares of the biopharmaceutical company’s stock worth $804,000 after acquiring an additional 13,596 shares in the last quarter. Stock Yards Bank & Trust Co. raised its position in Pfizer by 0.7% during the second quarter. Stock Yards Bank & Trust Co. now owns 123,800 shares of the biopharmaceutical company’s stock worth $4,159,000 after acquiring an additional 832 shares in the last quarter. Factory Mutual Insurance Co. raised its position in Pfizer by 2.1% during the second quarter. Factory Mutual Insurance Co. now owns 2,935,897 shares of the biopharmaceutical company’s stock worth $98,617,000 after acquiring an additional 60,000 shares in the last quarter. Prentiss Smith & Co. Inc. raised its position in Pfizer by 4.0% during the second quarter. Prentiss Smith & Co. Inc. now owns 15,548 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 600 shares in the last quarter. Finally, Capstone Asset Management Co. raised its position in Pfizer by 79.4% during the second quarter. Capstone Asset Management Co. now owns 342,493 shares of the biopharmaceutical company’s stock worth $11,504,000 after acquiring an additional 151,626 shares in the last quarter. 69.75% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Inc. (NYSE PFE) opened at $37.18 on Thursday. The firm has a market cap of $218,161.88, a PE ratio of 22.95, a PEG ratio of 2.45 and a beta of 1.01. Pfizer Inc. has a 1 year low of $30.90 and a 1 year high of $37.37. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.61 earnings per share. sell-side analysts predict that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

Pfizer declared that its board has approved a stock buyback plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.66%. Pfizer’s dividend payout ratio is 79.01%.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock worth $1,065,220 over the last 90 days. 0.06% of the stock is currently owned by corporate insiders.

Several analysts have issued reports on the stock. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. JPMorgan Chase & Co. set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Thursday, November 16th. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research report on Tuesday, January 2nd. Finally, Morgan Stanley set a $41.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Friday, January 5th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $38.94.

TRADEMARK VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2018/01/18/keybank-national-association-oh-cuts-stake-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related stocks with our FREE daily email newsletter.